Similar articles

• Low-dose imipramine for treatment of panic disorder during pregnancy: a retrospective chart review.

  Uguz F, Sahingoz M, Gungor B, Askin R. Uguz F, et al. J Clin Psychopharmacol. 2014 Aug;34(4):513-5. doi: 10.1097/JCP.0000000000000148. J Clin Psychopharmacol. 2014. PMID: 24875076
• Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome.

  Gurguis GN, Blakeley JE, Antai-Otong D, Vo SP, Orsulak PJ, Petty F, Rush AJ. Gurguis GN, et al. J Psychiatr Res. 1999 Jul-Aug;33(4):309-22. doi: 10.1016/s0022-3956(99)00008-4. J Psychiatr Res. 1999. PMID: 10404469 Review.
• Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.

  Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C. Mavissakalian MR, et al. Biol Psychiatry. 1998 Jun 1;43(11):848-54. doi: 10.1016/s0006-3223(97)00376-4. Biol Psychiatry. 1998. PMID: 9611676
• The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.

  Marchesi C, Ampollini P, Signifredi R, Maggini C. Marchesi C, et al. Neuropsychobiology. 1997;36(1):25-31. doi: 10.1159/000119356. Neuropsychobiology. 1997. PMID: 9211441
• [Panic attacks and panic disorder. Diagnostic criteria, prevalence, etiopathogenesis, clinical presentation and treatment].

  Rabe-Jabłońska J. Rabe-Jabłońska J. Psychiatr Pol. 1993 Mar-Apr;27(2):165-79. Psychiatr Pol. 1993. PMID: 8378469 Review. Polish. No abstract available.